US Drug Recall Register
Class III · Low risk Terminated Initiated Jun 2, 2017 (9 years ago)

G & W Clobetasol Propionate Ointment 0.05%

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed impurities/degradation specifications: This product is being recalled due to out of specification results for Clobetasol Related Compound A, a known impurity which is a degradation product.

What was recalled

G & W Clobetasol Propionate Ointment 0.05%, packaged in a) 15 g tube (NDC 0713-0656-15), b) 30 g tube (NDC 0713-0656-31, c) 45 g tube (NDC 0713-0656-37), d) 60 g tube (NDC 0713-0656-60), Rx Only, Manufactured by G & W Laboratories, Inc. 111 Coolidge Street, South Plainfield, NJ 07080

Recalling firm
G & W Laboratories, Inc.
NDC code
0713-0656-15
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0945-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Clobetasol recalls

See all
Class II · Moderate risk Ongoing

Clobetasol Propionate Shampoo

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0796-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Ointment

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0795-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Cream

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0794-2023
Class III · Low risk Terminated

Clobetasol propionate Cream USP

Reason Subpotent Drug: Low assay result observed during long-term stability testing.

Lupin Pharmaceuticals Inc. NDC 68180-956-03 D-0174-2023
Class II · Moderate risk Terminated

Clobetasol Propionate Lotion 0.05%

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Preferred Pharmaceuticals, Inc. NDC 68788-7768-01 D-0768-2022